title: Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
abstract: OBJECTIVE
  Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV). Because of the variable and sometimes inconsistent results, we performed a meta-analysis to estimate the association between these factors.
  
  
  METHODS
  We conducted a search of the literature published prior to July 1, 2014. The pooled results were analyzed as the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) using random-effect model.
  
  
  RESULTS
  The pooled results revealed that the rs368234815 TT/TT genotype was significantly correlated with SVR in HCV-1/4-infected Caucasian patients (OR=4.65, 95% CI=3.36-6.42, P<0.00001) but not in HCV-2/3-infected Caucasian patients (OR=1.44, 95% CI: 0.89-2.33, P=0.13). Conversely, the rs368234815 ΔG/ΔG genotype was significantly linked to treatment failure in Caucasian patients (OR=0.49, 95% CI: 0.38-0.64, P<0.00001), regardless of the HCV genotype.
  
  
  CONCLUSIONS
  The results of the meta-analysis suggest that IFNL4 rs368234815 polymorphism may be a predictor of SVR in Caucasian HCV-1/4-infected patients.
authors.affiliation: Division of General Surgery, First Affiliated Hospital, Nanyang Medical College, Nanyang 473000, He'nan, China. Electronic address: doctorxiexiao@163.com.
authors.forename: Xiao
authors.initials: X
authors.lastname: Xie
authors.affiliation: Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. Electronic address: doctorzhangling@163.com.
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Prevention and Health Care, Zhongshan Hospital, Chongqing, China.
authors.forename: Yin-Zhi
authors.initials: YZ
authors.lastname: Chen
mesh_terms: D000956:Antigens, Viral / Q000276:immunology; D020022:Genetic Predisposition to Disease; D019698:Hepatitis C, Chronic / Q000235:genetics* / Q000276:immunology / Q000628:therapy; D006801:Humans; D007109:Immunity / Q000187:drug effects; D016898:Interferon-alpha / Q000627:therapeutic use; D007378:Interleukins / Q000235:genetics*; D011092:Polyethylene Glycols / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D000095022:Interferon Lambda
chemical_list: D000956:Antigens, Viral; D016898:Interferon-alpha; D007378:Interleukins; D011092:Polyethylene Glycols; D012254:Ribavirin; C579163:IFNL4 protein, human; D000095022:Interferon Lambda; C571406:PEG-IFN-SA
keywords: CHC; IFNL4; Meta-analysis; PEG-IFN/RBV; SVR